BXB.AU

20.83

-1%↓

WOR.AU

12.12

+0.5%↑

BKW.AU

25.19

+2.32%↑

BXB.AU

20.83

-1%↓

WOR.AU

12.12

+0.5%↑

BKW.AU

25.19

+2.32%↑

BXB.AU

20.83

-1%↓

WOR.AU

12.12

+0.5%↑

BKW.AU

25.19

+2.32%↑

BXB.AU

20.83

-1%↓

WOR.AU

12.12

+0.5%↑

BKW.AU

25.19

+2.32%↑

BXB.AU

20.83

-1%↓

WOR.AU

12.12

+0.5%↑

BKW.AU

25.19

+2.32%↑

Search

CSL Ltd

Slēgts

SektorsRūpniecība

240.84 0.87

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

240.15

Max

241.19

Galvenie mērījumi

By Trading Economics

Ienākumi

1.3B

2B

Pārdošana

1.5B

8.2B

P/E

Sektora vidējais

27.633

34.415

EPS

1.831

Dividenžu ienesīgums

1.77

Peļņas marža

24.437

Darbinieki

32,698

EBITDA

1.5B

3.2B

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt (spēcīgs)

Prognoze 12 mēnešiem

+33.1% upside

Dividendes

By Dow Jones

Dividenžu ienesīgums

Sektora vidējais

1.77%

2.91%

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

-21B

115B

Iepriekšējā atvēršanas cena

239.97

Iepriekšējā slēgšanas cena

240.84

CSL Ltd Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 9. apr. 09:39 UTC

Galvenie tirgus virzītāji

Pharma Stocks Tumble After Trump Threatens Tariffs on Medicines

2025. g. 10. febr. 21:55 UTC

Peļņas

CSL Lifts 1st Half Net Profit by 3%, Led by Blood-Plasma Business -- Update

2025. g. 10. febr. 21:34 UTC

Peļņas

CSL Lifts 1st Half Net Profit by 3%, Led by Blood-Plasma Business

2024. g. 12. aug. 23:23 UTC

Peļņas

CSL Annual Profit Rises by 20% on Immunoglobulins Growth -- Update

2024. g. 12. aug. 22:49 UTC

Peļņas

CSL Annual Profit Rises by 20%, Forecasts Fiscal Year 2025 Underlying Earnings Growth

2025. g. 9. apr. 07:01 UTC

Tirgus saruna

CSL May Need to Raise Prices to Offset Trump's Potential Pharma Tariffs -- Market Talk

2025. g. 21. marts 02:03 UTC

Tirgus saruna

Severe U.S. Influenza Season Could Benefit CSL -- Market Talk

2025. g. 11. febr. 22:30 UTC

Tirgus saruna

Flu Vaccines Proving Problematic for CSL -- Market Talk

2025. g. 10. febr. 21:40 UTC

Peļņas

CSL Lifts 1H Net Profit by 3%, Led by Blood-Plasma Business -- Update

2025. g. 10. febr. 21:19 UTC

Peļņas

CSL Lifts 1H Net Profit by 3%, Led by Blood-Plasma Business

2025. g. 10. febr. 21:13 UTC

Peļņas

CSL Reaffirms Guidance for FY 2025 Net Profit of US$3.2 Billion-US$3.3 Billion at Constant FX

2025. g. 10. febr. 21:12 UTC

Peļņas

CSL Interim Dividend US$1.30/Security

2025. g. 10. febr. 21:12 UTC

Peļņas

CSL 1H Revenue US$8.48 Billion, Up 5% on Year

2025. g. 10. febr. 21:11 UTC

Peļņas

CSL 1H Net Profit US$2.07 Billion, Up 3% on Year

2024. g. 7. nov. 03:53 UTC

Tirgus saruna

U.S. Tariffs Could Force Moves by Australian Med-Techs -- Market Talk

2024. g. 22. okt. 22:53 UTC

Tirgus saruna

CSL's R&D Update Seen as Neutral Overall -- Market Talk

2024. g. 10. okt. 22:20 UTC

Tirgus saruna

CSL Bull Looking for Update on Gross Margin -- Market Talk

2024. g. 13. aug. 00:33 UTC

Tirgus saruna

CSL Profit Outlook Looks Weaker Than Expected -- Market Talk

2024. g. 12. aug. 22:34 UTC

Peļņas

CSL Annual Profit Rises by 20%, Forecasts FY 2025 Underlying Earnings Growth

2024. g. 12. aug. 22:18 UTC

Peļņas

CSL Expects FY2025 Revenue Growth of Roughly 5%-7% at Constant Currency

2024. g. 12. aug. 22:18 UTC

Peļņas

CSL: Conditions for Seqirus Remain Challenging, But Unit Expected to Outperform Market

2024. g. 12. aug. 22:17 UTC

Peļņas

CSL: Has a Number of Efficiency Initiatives Underway in Plasma Collections, Manufacturing Operations

2024. g. 12. aug. 22:16 UTC

Peļņas

CSL: Momentum in Behring Seen Underpinned by Strong Patient Demand in Immunoglobulins

2024. g. 12. aug. 22:15 UTC

Peļņas

CSL: Remains Confident in Medium-Term Double-Digit Earnings Growth Target

2024. g. 12. aug. 22:14 UTC

Peļņas

CSL: Vifor Continues to Grow Iron Volume in Europe Despite Generic Entrants

2024. g. 12. aug. 22:13 UTC

Peļņas

CSL Expects FY2025 Underlying Profit Up Between 10%-13% on Constant Currency Basis

2024. g. 12. aug. 22:13 UTC

Peļņas

CSL Expects FY2025 Underlying Profit Between US$3.2 Billion-US$3.3 Billion

2024. g. 12. aug. 22:11 UTC

Peļņas

CSL: Outlook for Behring Positive But Competitive Pressures Increased Recently

2024. g. 12. aug. 22:10 UTC

Peļņas

CSL FY Underlying Profit Up 15% on Constant Currency Basis to US$3.01 Billion

2024. g. 12. aug. 22:09 UTC

Peļņas

CSL FY Revenue US$14.80 Billion, Up 11% On-Year

Salīdzinājums

Cenas izmaiņa

CSL Ltd Prognoze

Cenas mērķis

By TipRanks

33.1% augšup

Prognoze 12 mēnešiem

Vidējais 314.861 AUD  33.1%

Augstākais 360.3 AUD

Zemākais 250 AUD

Pamatojoties uz 14 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi CSL Ltd — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

14 ratings

12

Pirkt

2

Turēt

0

Pārdot

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par CSL Ltd

CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants. The CSL Seqirus segment provides influenza related products and pandemic services to governments. The CSL Vifor segment offers products in the therapeutic areas of iron deficiency and nephrology. The company also licenses CSL intellectual property. CSL Limited was founded in 1916 and is headquartered in Melbourne, Australia.